Citi analyst Samantha Semenkow raised the firm’s price target on Nektar (NKTR) to $123 from $102 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q4 report. Nektar announced plans to advance rezpeg into a Phase 3 program for atopic dermatitis next quarter, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTR: